First-ever international guidelines for psoriatic arthritis treatment publishedOctober 27th, 2008 - 12:27 pm ICT by ANI
Washington, October 27 (ANI): A group of rheumatologists, dermatologists, and patient advocates has published the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.
Group leader Dr. Christopher Ritchlin, professor of Medicine at the University of Rochester Medical Center, says that a broad range of treatments is available to treat the disease, including non-steroidal anti-inflammatory drugs like ibuprofen and steroids injected into joints or tendons.
He adds that other anti-inflammatory medications known as disease-modifying antirheumatic drugs, such as methotrexate, are often used.
The researcher, however, insists that his Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has found that the medications are often not effective for psoriatic arthritis, even though they can be very useful for treating rheumatoid arthritis.
According to the group, patients should see a specialist, such as a dermatologist or rheumatologist, as soon as psoriasis or psoriatic arthritis is suspected.
Ritchlin highlights the fact that, currently, a large number of patients with psoriatic arthritis do not see a rheumatologist, and many go undiagnosed.
The group has also suggested that doctors consider newer medications that inhibit a molecule known as TNF (tumor necrosis factor).
“Most people respond rapidly and dramatically to these medications,” said Ritchlin, who led a research team at Rochester that described the central role of TNF in the bone damage that occurs in psoriatic arthritis.
Recent estimates indicate that less than 20 percent of psoriatic arthritis patients are on anti-TNF medications.
The group presented its guidelines at the annual meeting of the American College of Rheumatology on Sunday. (ANI)
- Engineered protein has potential for new anti- inflammatory treatment - Mar 11, 2011
- Largest single collection of psoriasis DNA samples offers hope to sufferers - Sep 02, 2010
- Study clears misconception linked to joint pain from breast cancer drugs - Nov 08, 2010
- Positive outcomes in rheumatoid arthritis linked to early diagnosis - Nov 24, 2010
- Rheumatoid arthritis medication linked to increased risk for shingles - Feb 18, 2009
- Tumeric derivative found promising in tendinitis - Aug 11, 2011
- Ibuprofen may reduce risk of Parkinson's disease - Mar 03, 2011
- 'Master switch' for key immune cells in inflammatory diseases found - Jan 17, 2011
- Ibuprofen could treble stroke risk - Jan 12, 2011
- Experimental non-steroidal treatment of asthma holds promise - Jul 02, 2010
- Anti-inflammatory drugs reduce effectiveness of antidepressants - Apr 26, 2011
- Four new psoriasis 'hotspots' identified - Oct 19, 2010
- Manipulating muscle stem cells could treat muscular dystrophy - Oct 10, 2010
- Painkillers shoot up death risk in heart attacks - May 10, 2011
- 'Ibuprofen promotes bone healing post fracture' - Jul 04, 2012
Tags: american college of rheumatology, anti inflammatory drugs, anti inflammatory medications, antirheumatic drugs, arthritis patients, arthritis treatment, bone damage, dermatologist, dermatologists, dr christopher, grappa, methotrexate, non steroidal anti inflammatory drugs, patient advocates, psoriatic arthritis, rheumatoid arthritis, rochester medical center, tumor necrosis factor, university of rochester, university of rochester medical center